Intercept Pharmaceuticals Inc (ICPT): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Intercept Pharmaceuticals ( ICPT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Intercept Pharmaceuticals rose $27.04 (7.1%) to $406.11 on light volume. Throughout the day, 608,516 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 822,400 shares. The stock ranged in a price between $378.01-$414.99 after having opened the day at $380.86 as compared to the previous trading day's close of $379.07. Other companies within the Drugs industry that increased today were: Anika Therapeutics ( ANIK), up 33.2%, Amyris ( AMRS), up 26.4%, Prana Biotechnology ( PRAN), up 19.9% and Cormedix ( CRMD), up 14.2%.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $7.2 billion and is part of the health care sector. Shares are up 446.5% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

On the negative front, Cerus Corporation ( CERS), down 17.2%, InterMune ( ITMN), down 14.9%, Biocryst Pharmaceuticals ( BCRX), down 7.6% and Jazz Pharmaceuticals ( JAZZ), down 7.4% , were all laggards within the drugs industry with Celgene Corporation ( CELG) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Investors Shun Biotech Stocks

Investors Shun Biotech Stocks

Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers

Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)